

HERTFORDSHIRE AND WEST ESSEX AREA PRESCRIBING COMMITTEE (APC)

ELTROMBOPAG FOR THE TREATMENT OF THROMBOCYTOPENIA IN ADULTS WITH HEPATITIS C – **RESTRICTED RECOMMENDATION**

Name: generic (trade)	What it is	Indication	Date decision last revised	Decision Status	NICE / SMC Guidance
Eltrombopag (Revolade®)	Thrombopoietin receptor agonist	Treatment of thrombocytopenia in adults with chronic hepatitis C virus (HCV) infection where the degree of thrombocytopenia is inhibiting or impeding adequate treatment of hepatitis C infection with interferon-based therapy.	HMMC April 2015	Final	SMC – restricted recommendation

Recommendation:

RECOMMENDED FOR RESTRICTED USE, FOR INITIATION AND CONTINUATION IN SECONDARY CARE.

NOT RECOMMENDED FOR PRIMARY CARE PRESCRIBING

- **Eltrombopag is RECOMMENDED** for the treatment of thrombocytopenia in adult patients with chronic hepatitis C virus infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.
- Applications for funding should be made on an patient specific funding proforma.

At HMMC, April 2015, the committee agreed to adopt the East of England Priorities Advisory Committee recommendation for eltrombopag to treat thrombocytopenia associated with chronic hepatitis C.

<p><u>EFFICACY</u></p> <ul style="list-style-type: none"> • Two double-blind, randomised, controlled studies in patients with chronic hepatitis C virus infection and thrombocytopenia demonstrated significantly higher sustained viral response rates in patients who continued treatment with eltrombopag during interferon-based antiviral therapy than in those patients whose eltrombopag treatment was discontinued on initiation of antiviral therapy. 	<p><u>SAFETY</u></p> <ul style="list-style-type: none"> • During trials, the safety profile mainly reflected the toxicity profiles of concomitant therapies, ribavirin and peginterferon. • The SPC for Revolade® notes an increased risk of adverse effects, including potentially fatal hepatic decompensation and thromboembolic events.
<p><u>COST</u></p> <ul style="list-style-type: none"> • Cost/patient/course of antiviral therapy: £3850-£30,030 at dose of 25-75mg once daily. • Cost-effectiveness was calculated in the SMC review and was considered to be demonstrated if the treatment was made available at the price agreed in the Patient Access Scheme. 	<p><u>PATIENT FACTORS</u></p> <ul style="list-style-type: none"> • None identified.

Assessment against Ethical Framework

Clinical effectiveness

Two double-blind, randomised, controlled studies (n=956) in patients with chronic hepatitis C virus infection and thrombocytopenia demonstrated significantly higher sustained viral response rates in patients who continued treatment with eltrombopag during interferon-based antiviral therapy than in those patients whose eltrombopag treatment was discontinued on initiation of antiviral therapy.

Cost effectiveness

Considered to be cost effective by SMC when available to the NHS at the confidential Patient Access Scheme Price.

Needs of the population

The needs of the population are low. Other newer treatments for hepatitis C are emerging with lower rates of thrombocytopenia so fewer patients are treated with interferon-based therapy.

Needs of the community

The needs of the community are low as the treatment will affect a small population and is unlikely to affect the resources available for treatment of other conditions for the wider community.

Policy drivers

None

Equity

No issues identified.

References

- The East of England Priorities Advisory Committee Guidance statement, Eltrombopag, <https://www.prescqipp.info/our-resources/webkits/pac-eeo/>
- Summary of Product Characteristics -Revolade®, GlaxoSmithKline UK, 04 June 2014. <https://www.medicines.org.uk/emc/medicine/22949>
- Scottish Medicines Consortium review. Eltrombopag in adult patients with chronic hepatitis C virus infection, for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy. November 2013. <https://www.scottishmedicines.org.uk/medicines-advice/eltrombopag-revolade-fullsubmission-91913/>

Version	2.0 Harmonisation of Hertfordshire Medicines Management Committee (HMMC) guidance and West Essex Medicines Optimisation Programme Board (WEMOPB) guidance updates include: <ul style="list-style-type: none"> • Rebadging with HWE ICB and removal of ENHCCG and HVCCG headers
Developed by	Hertfordshire Pharmacy and Medicines Optimisation Teams East and North Herts CCG and NHS Herts Valleys CCG
Approved by	HMMC
Date approved/updated	April 2015
Review date:	The recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available.
Superseded version	1.0 Approved April 2015